抗CD38单克隆抗体清除CD38阳性调节性T细胞可使浆细胞病患者对SARS-CoV-2疫苗接种产生持久应答
本研究在60例浆细胞病患者中探讨CD38阳性调节性T细胞(Treg)与mRNA-COVID-19疫苗接种的关系。接受抗CD38单克隆抗体治疗者CD38阳性Treg显著低于未接受者(0.9 vs. 13.2/μl)。迟发应答者CD38阳性Treg计数显著低于非迟发应答者(2.5 vs. 10.3/μl),且CD38阳性Treg较低者抗体滴度从第4-12周维持,较高者则下降。
要点
- 抗CD38单克隆抗体治疗者CD38阳性Treg显著低于未治疗者(0.9 vs. 13.2/μl)。
- 迟发应答者CD38阳性Treg显著低于非迟发应答者(2.5 vs. 10.3/μl)。
- CD38阳性Treg较低者抗体滴度从第4-12周维持,较高者下降。
核心结论
- 抗CD38单克隆抗体清除CD38阳性Treg可能使浆细胞病患者对mRNA-COVID-19疫苗接种产生持久应答。
研究设计与样本
- 本研究在60例浆细胞病患者中分析CD38阳性调节性T细胞与mRNA-COVID-19疫苗接种的关系。
主要发现
- 接受抗CD38单克隆抗体治疗者CD38阳性Treg显著低于未接受者(0.9 vs. 13.2/μl)。
- 迟发应答者(第二剂疫苗接种后第4-12周抗体滴度升高)CD38阳性Treg计数显著低于非迟发应答者(2.5 vs. 10.3/μl)。
- CD38阳性Treg水平较低的患者抗体滴度从第4-12周维持,而CD38阳性Treg水平较高的患者抗体滴度下降。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study reports the relationship between CD38+ regulatory T cells (Tregs) and messenger RNA coronavirus disease 2019 (mRNA-COVID-19) vaccination in 60 patients with plasma cell dyscrasia. Patients treated with anti-CD38 monoclonal antibodies (mAbs) had significantly lower CD38+ Tregs than those not treated (0.9 vs. 13.2/μl). Late-responders, whose antibody titres increased from weeks 4-12 after the second vaccination, had significantly lower CD38+ Treg counts than non-late-responders (2.5 vs. 10.3/μl). Antibody titres in patients with lower CD38+ Treg levels were maintained from weeks 4-12 but decreased in those with higher CD38+ Treg levels. Therefore, depletion of CD38+ Tregs by anti-CD38 mAbs may induce a durable response to mRNA-COVID-19 vaccination.
引用
- Terao T, Naduka T, Ikeda D, et al. Depletion of CD38-positive regulatory T cells by anti-CD38 monoclonal antibodies induces a durable response to SARS-CoV-2 vaccination in patients with plasma cell dyscrasia. Br J Haematol. 2022. PMID: 35172374. doi:10.1111/bjh.18079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。